Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the effects of valproic acid on immune cell activation and gene expression, potentially influencing infection outcomes and suggesting its promise for autoimmune and hypersensitivity condition management.

This study identified peripheral myeloid cells as the earliest dysregulated immune cells in PINK1 KO mice with Parkinson’s-like symptoms following intestinal infections, suggesting that PINK1 regulates gut immune functions linked to early Parkinson’s disease mechanisms.

This study found that long-term exposure to sodium valproate can increase oxidative stress and inflammation in rat stomach tissues, while treatment with rutin, a natural antioxidant, was associated with reduced markers of these effects at dosages of 50 mg/kg and 100 mg/kg.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

This study discusses a hypothesis for repurposing non-cancer drugs and combining micronutrients to target cancer and cancer stem cells with fewer side effects, suggesting a potential new approach for more effective cancer therapy.

This study found that Tibetan cashmere goats have genetic adaptations that contribute to their finer cashmere, possibly enhancing their ability to withstand the cold climate of the Tibetan plateau, while identifying specific genes related to hair growth, pigmentation, and heart development.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

This review discusses selection signatures and selective sweeps in fiber-producing animals and recommends further genomic investigations to identify genes related to important fiber traits, without providing new results.

In this study, researchers found that the SLICK1 allele in cattle may alter local immune regulation, hair growth, and tissue remodeling, as indicated by differential gene expression pathways associated with immune and inflammatory responses in slick vs. nonslick Holsteins.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.

In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.

This review discusses recent findings on the pathology, diagnosis, and treatment of inflammatory bowel disease and reports no new clinical results.

This review discusses mechanisms of wound healing impairment in leptin-deficient murine models used for diabetic research, and reports no new clinical results; the authors emphasize the need for further study.

This study found that dutasteride affected spinal bone formation in curdlan-treated SKG mice, while DHT treatment reduced osteoblast differentiation in vitro, suggesting that DHT inhibition might unexpectedly increase spinal ankylosis progression in ankylosing spondylitis patients.

This review discusses the plasticity of stem cell populations and their ability to switch between functions for tissue homeostasis and regeneration, emphasizing environmental and hormonal influences, and reports no new results.

This review discusses the role of lncRNA Xist in cell growth regulation and disease development, particularly cancer, and reports no new experimental results.

This review highlights the ongoing challenges and advancements in developing precise and early intervention strategies for autoimmune diseases and emphasizes the need for more personalized and disease-specific therapies.

In this paper, Chemistry42—a software integrating AI with computational and medicinal chemistry—demonstrated efficiency in designing novel molecular structures targeting DDR1 and CDK20, with properties validated in both in vitro and in vivo studies.